{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:50:51Z","timestamp":1793451051046,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1245\/s10434-025-19065-z","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:24:51Z","timestamp":1768933491000},"page":"3244-3253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evolution of Breast Cancer Treatment 2010\u20132023"],"prefix":"10.1245","volume":"33","author":[{"given":"Courtney N.","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3228","authenticated-orcid":false,"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"6","key":"19065_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/genes13060960","volume":"13","author":"J Ben-Dror","year":"2022","unstructured":"Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment. Genes (Basel). 2022;13(6):960.","journal-title":"Genes (Basel)"},{"key":"19065_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233\u201341.","journal-title":"N Engl J Med."},{"key":"19065_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567\u201375.","journal-title":"N Engl J Med."},{"key":"19065_CR4","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1245\/s10434-016-5370-5","volume":"23","author":"TJ Hieken","year":"2016","unstructured":"Hieken TJ, Boolbol SK, Dietz JR. Nipple-sparing mastectomy: indications, contraindications, risks, benefits, and techniques. Ann Surg Oncol. 2016;23(10):3138\u201344.","journal-title":"Ann Surg Oncol."},{"key":"19065_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA."},{"key":"19065_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558\u201366.","journal-title":"Ann Surg."},{"key":"19065_CR7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657\u201363.","journal-title":"J Clin Oncol."},{"key":"19065_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375.","journal-title":"JAMA."},{"key":"19065_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557\u201364.","journal-title":"JAMA Oncol."},{"key":"19065_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer - Primary results of the INSEMA trial. N Engl J Med. 2025;392(11):1051\u201364.","journal-title":"N Engl J Med."},{"key":"19065_CR11","unstructured":"Society of surgical oncology. Five things physicians and patients should question, 2021, 5\/30\/2023. Retrieved 9\/15\/2025."},{"issue":"Suppl 1","key":"19065_CR12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6605268","volume":"101","author":"M Verrill","year":"2009","unstructured":"Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer. 2009;101(Suppl 1):S2-5.","journal-title":"Br J Cancer."},{"key":"19065_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778\u201385.","journal-title":"J Clin Oncol."},{"issue":"10","key":"19065_CR14","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.3390\/ijms21103528","volume":"21","author":"G Barchiesi","year":"2020","unstructured":"Barchiesi G, Mazzotta M, Krasniqi E, et al. Neoadjuvant Endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci. 2020;21(10):3528.","journal-title":"Int J Mol Sci."},{"key":"19065_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451\u201367.","journal-title":"Lancet."},{"key":"19065_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ."},{"key":"19065_CR17","unstructured":"American college of surgeons national cancer database tools (2022). 2022"},{"key":"19065_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XCS.0000000000001214","volume":"240","author":"EB Habermann","year":"2025","unstructured":"Habermann EB, Day CN, Palis BE, et al. American College of Surgeons Cancer Program annual report from 2021 participant user file. J Am Coll Surg. 2025;240(1):95\u2013110.","journal-title":"J Am Coll Surg."},{"key":"19065_CR19","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","volume":"31","author":"BE Palis","year":"2024","unstructured":"Palis BE, Janczewski LM, Browner AE, et al. The national cancer database conforms to the standardized framework for registry and data quality. Ann Surg Oncol. 2024;31(9):5546\u201359.","journal-title":"Ann Surg Oncol."},{"key":"19065_CR20","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1200\/JCO.2009.27.6774","volume":"28","author":"EB Habermann","year":"2010","unstructured":"Habermann EB, Abbott A, Parsons HM, et al. Are mastectomy rates really increasing in the United States? J Clin Oncol. 2010;28(21):3437\u201341.","journal-title":"J Clin Oncol."},{"key":"19065_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamasurg.2020.0322","volume":"155","author":"T Wang","year":"2020","unstructured":"Wang T, Baskin AS, Dossett LA. Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 2020;155(8):759\u201370.","journal-title":"JAMA Surg."},{"key":"19065_CR22","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1245\/s10434-010-1091-3","volume":"17","author":"K Yao","year":"2010","unstructured":"Yao K, Stewart AK, Winchester DJ, et al. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998\u20132007. Ann Surg Oncol. 2010;17(10):2554\u201362.","journal-title":"Ann Surg Oncol."},{"key":"19065_CR23","doi-asserted-by":"publisher","first-page":"44S","DOI":"10.1097\/PRS.0000000000003949","volume":"140","author":"AS Colwell","year":"2017","unstructured":"Colwell AS, Christensen JM. Nipple-Sparing mastectomy and direct-to-implant breast reconstruction. Plast Reconstr Surg. 2017;140:44S-50S.","journal-title":"Plast Reconstr Surg."},{"key":"19065_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149\u201360.","journal-title":"Lancet Oncol."},{"key":"19065_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer Jr","year":"2025","unstructured":"Geyer CE Jr, Untch M, Huang CS, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392(3):249\u201357.","journal-title":"N Engl J Med."},{"key":"19065_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med."},{"key":"19065_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485\u2013505.","journal-title":"J Clin Oncol."},{"key":"19065_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.surg.2021.10.033","volume":"171","author":"E Di Lena","year":"2022","unstructured":"Di Lena E, Hopkins B, Wong SM, et al. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: a multi-institutional matched historical cohort study. Surgery. 2022;171(3):666\u201372.","journal-title":"Surgery."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19065-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:45Z","timestamp":1773330465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19065-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["19065"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19065-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Judy Boughey reports research funding paid to institution from Eli Lilly, SimBioSys, and Quantum Leap Healthcare. Dr. Boughey is on the DSMC for Cairn Surgical. Dr. Boughey is supported by the W.H. Odell Professorship in Individualized Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}